Maverick Capital Ltd. Purchases New Stake in LivaNova PLC $LIVN

Maverick Capital Ltd. purchased a new stake in shares of LivaNova PLC (NASDAQ:LIVN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,044 shares of the company’s stock, valued at approximately $956,000.

Several other institutional investors also recently bought and sold shares of LIVN. Hantz Financial Services Inc. raised its stake in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares during the period. State of Wyoming purchased a new stake in LivaNova during the 2nd quarter worth $31,000. EverSource Wealth Advisors LLC boosted its position in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the period. Quarry LP acquired a new stake in LivaNova in the 3rd quarter valued at $36,000. Finally, Covestor Ltd increased its holdings in LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on LIVN. Robert W. Baird reduced their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. KeyCorp increased their target price on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Freedom Capital upgraded LivaNova to a “hold” rating in a report on Tuesday, June 30th. Zacks Research raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Mizuho upped their price target on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $81.38.

LivaNova Stock Performance

NASDAQ:LIVN opened at $82.09 on Wednesday. The firm has a 50-day moving average of $78.66 and a two-hundred day moving average of $69.83. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The stock has a market cap of $4.51 billion, a P/E ratio of 42.10 and a beta of 0.86. LivaNova PLC has a 1-year low of $41.01 and a 1-year high of $85.27.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. During the same period in the previous year, the company earned $0.88 earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, research analysts expect that LivaNova PLC will post 3.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.35% of the stock is currently owned by company insiders.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.